Horsham, United Kingdom

Catherine LeBlanc

USPTO Granted Patents = 14 


Average Co-Inventor Count = 5.4

ph-index = 5

Forward Citations = 48(Granted Patents)


Company Filing History:


Years Active: 2010-2015

Loading Chart...
Loading Chart...
14 patents (USPTO):Explore Patents

Title: Catherine LeBlanc: Pioneering Innovations in Pharmaceutical Compounds

Introduction: Catherine LeBlanc, a prolific inventor based in Horsham, GB, has made significant contributions to the field of pharmaceuticals with a total of 14 patents to her name. Her groundbreaking work revolves around developing heterocyclic derivatives that activate the IP receptor, offering promising treatment options for conditions such as pulmonary arterial hypertension (PAH) and pulmonary fibrosis.

Latest Patents: Among Catherine LeBlanc's recent patents is the creation of Substituted Pyrido[2,3-B]pyrazines as IP Receptor Agonists. These derivatives have shown potential in activating the IP receptor signaling pathway, presenting therapeutic benefits for PAH, pulmonary fibrosis, and fibrotic conditions in various organs. The pharmaceutical compositions she has formulated demonstrate efficacy in both animal models and patients, with compounds like those in Formula Ia standing out.

Career Highlights: Catherine LeBlanc has garnered expertise and recognition through her tenure at renowned companies such as Novartis AG. Her innovative approach to drug development and her consistent track record of patenting novel compounds have positioned her as a leading figure in the pharmaceutical industry. Her dedication to advancing treatments for challenging medical conditions has earned her widespread acclaim.

Collaborations: Throughout her career, Catherine LeBlanc has collaborated with esteemed colleagues like David Andrew Sandham and Nikolaus Johannes Stiefl. These partnerships have been instrumental in furthering her research and expanding the scope of her inventions. The synergy created by working alongside talented individuals has fueled her success and led to breakthroughs in pharmaceutical science.

Conclusion: Catherine LeBlanc's exceptional work in developing IP receptor agonists marks her as a trailblazer in the field of pharmaceutical innovations. Her patents not only showcase her technical prowess but also underline her commitment to improving healthcare outcomes for patients worldwide. With a strong foundation in research and a passion for discovery, Catherine LeBlanc continues to drive progress and shape the future of medicine.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…